SCHEMBL13028633

SCHEMBL13028633

CS(=O)(=O)OCCc1ccc(CCC#N)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 2/20 0.42
MMP13 P45452 1/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA1 P00915 6/20 0.40
CA2 P00918 6/20 0.40
CA9 Q16790 1/20 0.40
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
CA12 O43570 1/20 0.36
CA4 P22748 1/20 0.36
NLRP3 Q96P20 1/20 0.35
NR1H2 P55055 2/20 0.33
NR1H3 Q13133 2/20 0.33
CYP24A1 Q07973 1/20 0.31
APLNR P35414 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18697056 0.86 PKM (0.41) MMP9MEN1KMT2ACA1CA2
SCHEMBL3258334 0.85 CA2 (0.50) MMP9CA1CA2CA9KDM4E
SCHEMBL2961510 0.83 CYP2A6 (0.46) CA1CA2CA9TSHRCA12
SCHEMBL23649655 0.79 L3MBTL1 (0.43) MMP9MMP13MEN1KMT2ACA1
SCHEMBL17891745 0.78 CA2 (0.44) MMP9CA1CA2CA9KDM4E
SCHEMBL13527822 0.78 CA2 (0.50) MMP9MEN1KMT2ACA1CA2
SCHEMBL6991225 0.78 CA1 (0.48) MMP9MEN1KMT2ACA1CA2
SCHEMBL19972561 0.78 RORC (0.41) MMP9CA1CA2CA9KDM4E
SCHEMBL980388 0.77 CA1 (0.44) MMP9CA1CA2CA9KDM4E
SCHEMBL1284072 0.77 CA1 (0.43) MMP9MEN1KMT2ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340491-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2016-05-17 US disclosed
US-9340491-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2016-05-17 US disclosed
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US disclosed
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US disclosed
US-8338454-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2012-12-25 US disclosed
US-8338454-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2012-12-25 US disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 MMP9 2624/4885MMP13 3014/4885MEN1 2249/4885
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 MMP9 2624/4885MMP13 3014/4885MEN1 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.